Skip to main content

Table 4 Comparison of baseline characteristics between the CS less than 7.5 mg/day group and not

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables CS  7.5 mg at year 1 (n = 21) Not (n = 21) *P value
Male, n (%) 6/21 (28.6%) 9/21 (42.9) 0.5204
Age (years) 42.8 ± 13.6 33.1 ± 10.5 0.0166*
Disease duration (entero-BD, months) 42.4 ± 68.8 40.3 ± 26.2 0.1341
Multiple ulceration, n (%) 4/21 (19.1%) 10/21 (47.6%) 0.1001
History of relapse, n (%) 11/21 (52.4%) 13/21 (61.9%) 0.7557
History of perforation, n (%) 3/21 (14.3%) 3/21 (14.3%) 1.0000
History of surgery, n (%) 4/21 (19.1%) 3/21 (14.3%) 1.0000
Concomitant CS dose (mg/day) 22.7 ± 21.5 28.9 ± 17.1 0.1450
Concomitant colchicine use, n (%) 15/21 (71.4%) 10/21 (47.6%) 0.2082
Concomitant drug use, n (%) (MTX, MS/SSZ, AZ) 18/21 (85.7%) 15/21 (71.4%) 0.4537
Concomitant MTX use, n (%) 15/21 (71.4%) 3/21 (14.3%) 0.0004*
TNF-i use, n (%) 17/21 (81.0%) 3/21 (14.3%) < 0.0001*
DAIBD 70.0 ± 40.5 86.7 ± 25.3 0.0570
  1. Plus-minus values are means ± standard deviation. *P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease